Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.

Abstract

We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan, either at randomization (n=731) or post-randomization drop-in use (n=425), to evaluate the relationship between the efficacy and safety of combination therapy with vericiguat. The efficacy of vericiguat on the primary composite endpoint, heart failure (HF) hospitalization, and all-cause mortality was assessed. Safety outcomes included symptomatic hypotension, syncope, worsening renal function, and hyperkalaemia. At randomization, 731 patients received sacubitril/valsartan; they were more frequently from Western Europe or North America, had lower ejection fraction and systolic blood pressure, and more use of triple background HF therapy (65.9% vs. 58.6%), biventricular pacemakers (17.9% vs. 14.1%), or implantable cardioverter defibrillators (42.3% vs. 25.3%). For patients on versus not on sacubitril/valsartan at randomization, adjusted hazard ratios (95% confidence intervals) for vericiguat's treatment effect on the primary composite outcome, cardiovascular death, and HF hospitalization were 0.92 (0.71-1.19) versus 0.89 (0.80-0.98), 0.71 (0.45-1.12) versus 0.95 (0.82-1.11), and 0.98 (0.74-1.29) versus 0.87 (0.78-0.98), respectively. No significant interaction existed between sacubitril/valsartan and vericiguat's treatment effect (p-values for interaction: 0.81, 0.23 and 0.47, respectively). Post-randomization, more drop-in sacubitril/valsartan use occurred in those assigned to placebo (n=238) versus vericiguat (n=187) (p=0.007). Symptomatic hypotension (21.0% vs. 23.1%; p=0.41), renal dysfunction (29.9% vs. 31.9%; p=0.50), and hyperkalaemia (10.3% vs. 7.9%; p=0.20) in patients receiving sacubitril/valsartan (n=992) for ≥3months were not different by treatment arm. Concomitant use of sacubitril/valsartan for at least 3months did not alter the efficacy of vericiguat and was similarly safe and tolerated in both study arms. Sacubitril/valsartan was initiated more frequently after randomization in patients assigned to placebo versus vericiguat. ClinicalTrials.gov NCT02861534.